ArticlemSystems2022
Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant
Open access · goldAbstract read
In one paragraph
Article in mSystems, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Genomic Characterisation of Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter hormaechei Clinical Isolates from Nigeria: Evidence of Resistance, Virulence, and Putative Plasmid-Mediated Gene Sharing.Current microbiology · 2026Article
- Non-canonical gene amplifications facilitate adaptive evolution in bacteria.Nature microbiology · 2026Article
- Development of a stable low-copy mini F plasmid derivative for evaluating β-lactamase substrate specificity through antimicrobial susceptibility testing.Microbiology spectrum · 2026Article
- Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistantAntimicrobial agents and chemotherapy · 2026Article
- Article
- Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia.Microbiology spectrum · 2026Article
- A New Challenge of Antibiotic-Resistant Bacteria: Carbapenem-ResistantMicroorganisms · 2026Review
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- IncL plasmid-mediated dissemination of OXA-48 β-lactamase andJAC-antimicrobial resistance · 2026Article
- Large-scale plasmidome and carbapenem mobilome analysis reveals a mechanistic duality: high-power specialists and structural generalists mobile genetic elements.Frontiers in microbiology · 2026Article
- Article
- Unravelling mutation patterns in Extended-Spectrum β-Lactamases for precision drug design against AMR in Enterobacteriaceae.Molecular genetics and genomics : MGG · 2025Article
- Proteogenomic analysis demonstrates increasedAntimicrobial agents and chemotherapy · 2025Article
- Comprehensive Assessment of Initial Adaptation of Extended-Spectrum β-Lactamase-Positive ST131 Escherichia coli to Carbapenem Exposure.The Journal of infectious diseases · 2025Article
- Molecular Characterization of Extended-Spectrum ß-Lactamases-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Epidemiological Characteristics and Carbapenemase Analysis of Carbapenem-Resistant Enterobacterales Isolates in a Teaching Hospital in Guangzhou, China.Infection and drug resistance · 2025Article
- Revisiting the Metallo-International journal of microbiology · 2025Review
- Decadal Evolution of KPC-related plasmids in Pseudomonas aeruginosa high-risk clone ST463 in Zhejiang, China.Communications biology · 2024Article
- Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study.International journal of antimicrobial agents · 2024Article
- Analyzing Antibiotic Resistance in Bacteria from Wastewater in Pakistan Using Whole-Genome Sequencing.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
W C ShropshireDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.ORCID 0000-0001-8556-3248
A KonovalovaDepartment of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center at Houstongrid.267308.8, Houston, Texas, USA.ORCID 0000-0002-2238-8849
P McDaneldDivision of Pharmacy, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
M GohelDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
B StropeDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
P SahasrabhojaneDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
C N TranDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
D GreenbergDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-5101-3106
J KimDepartment of Bioinformatics, UT Southwestern Medical Center, Dallas, Texas, USA.
X ZhanDepartment of Bioinformatics, UT Southwestern Medical Center, Dallas, Texas, USA.
S AitkenDivision of Pharmacy, Michigan Medicine at University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-8659-4238
M BhattiDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.ORCID 0000-0001-5857-5825
T C SavidgeDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
T J TreangenDepartment of Computer Science, Rice University, Houston, Texas, USA.ORCID 0000-0002-3760-564X
B M HansonCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.ORCID 0000-0003-2949-7818
C A AriasDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0001-9054-9774
S A ShelburneDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.ORCID 0000-0001-9721-263X
The University of Texas MD Anderson Cancer Center · USSouthwestern Medical Center · USThe University of Texas Health Science Center at Houston · USBaylor College of Medicine · USMethodist Hospital · USMichigan Medicine · USRice University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MProject 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MBiogenesis of Surface-Exposed Lipoproteins in Gram-Negative BacteriaR01GM133904 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KONOVALOVA, ANNA · 2019 to 2023
$1.6MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MTexas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3MNovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995kMobile Genetic Elements and Clinical Outcomes in Staphylococcus aureus BacteremiaK01AI148593 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANSON, BLAKE M · 2020 to 2023
$519kRole of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant EnterobacteriaceaeR21AI151536 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2021 to 2022
$470kNCI NIH HHS P30 CA016672NIAID NIH HHS K01 AI148593NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI151536NIAID NIH HHS T32 AI141349NIGMS NIH HHS R01 GM133904NIH HHS S10 OD024977
Abstract
Noncarbapenemase-producing carbapenem-resistant
Indexed as
BacteremiaSepsisAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEscherichia coliGene AmplificationHumansInterspersed Repetitive SequencesKlebsiella pneumoniaePhylogenyPorinsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsPorinscarbapenem resistanceextended spectrum beta lactamasemobile genetic elementsmulti-drug resistanceosmoporin gene regulationoxford nanopore technologies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.